Brief: Ascentage Pharma Says Mdm2-P53 Inhibitor APG-115 Granted Fast Track Designation By U.S FDA
23/09/2021 24:32
Sept 23 (Reuters) - Ascentage Pharma Group International
6855.HK :
* ASCENTAGE PHARMA GROUP INTERNATIONAL - MDM2-P53 INHIBITOR
APG-115 GRANTED FAST TRACK DESIGNATION BY US FDA
Source text for Eikon: ID:nHKS3fWD3x
Further company coverage: 6855.HK
(Reuters.briefs@thomsonreuters.com)
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up